Shares Issued
As at 2 February 2023, the number of shares in issue was 1,141,999,321.
Significant Shareholders
As at 2 February 2023
None known at present time except for Director shareholdings (see below).
Director Shareholdings
As at 2 February 2023
| Director | Number | Ordinary Shares % |
|---|---|---|
| Alexis Sandler | 75,090,685 | 6.58 |
| Dr Vladislav Sandler | 41,544,677 | 3.64 |
| Peter Redmond | 5,596,270 | 0.49 |
Shares Not In Public Hands
Insofar as it is aware, as at 2 February 2023, 16.74% of the Company’s securities were not in public hands.
UK City Code On Takeovers And Mergers
The Company is subject to the provisions of the City Code on Takeovers and Mergers.
Shareholder Circulars
Annual and Half Year Reports, together with historical general meeting notices, blank proxy voting forms, and other shareholder circulars, may be found here: Annual and Half Year Reports.
Most recent shareholder circular:
| 8 June 2022 | Notice of Annual General Meeting to be held on 30 June 2022 and 2021 Equity Incentive Plan with Non-Employee Sub-Plan proposed for approval at the AGM |
Other Exchanges And Trading Platforms
Hemogenyx Pharmaceuticals plc has not applied or agreed to have any of it securities admitted or traded on any other exchanges or trading platforms.